Carvedilol and Metoprolol in Acute Myocardial Infarction Early Effect of Oxidized LDL and Paraoxonase-1 Activity

Year 2013, Volume: 2 Issue: 3, 179 - 184, 01.09.2013

Sezgin Albayrak Kemal Karaağaç İbrahim Baran Zeynel Abidin Yetgin Hakan Uçar Ali Aydınlar

https://doi.org/10.5505/abantmedj.2013.30592

Abstract

Objective: The aim of this study to investigate the effects of Carvedilol and Metoprolol on oxidized low density lipoprotein oxLDL and paraoxonase-1 PON-1 activity in patients with acute myocardial infarction who were treated with these agents for four weeks. Method: 31 patients with AMI and 15 healhty subjects for control group were contained. 15 patients of AMI group were given Carvedilol treatment and the remained 16 were given Metoprolol treatment and the study was randomized to two groups. At the end of the study oxLDL and PON-1 activity levels were studied from the blood samples taken at admission pre treatment and samples taken after one month treatment. Results: In patient group initial high density lipoprotein HDL level and PON-1 activity were found significantly lower but oxLDL level was higher in patient group compared to control group. The oxLDL levels were found to decrease in patient group after Carvedilol p=0,008 and Metoprolol p Conclusion: In paralel to other studies we showed that oxLDL is increased and HDL and PON-1 activity is decreased in patients with AMI. Carvedilol may be expected to be superior to Metoprolol due to its antioxidant effect in increasing PON-1 acitvity. But one month period may not be enough to determine this effect.

Keywords

Coronary Artery Disease, oxidized LDL, paraoxonase-1

Akut Miyokard İnfarktüsünde Karvedilol ve Metoprolol’ün Okside LDL ve Paraoksonaz-1 Aktivitesine Erken Dönem Etkisi

Abstract

Amaç: Bu çalışmanın amacı akut miyokard infarktüsü AMİ geçiren hastalarda dört haftalık karvedilol ve metoprolol tedavisinin okside düşük yoğunluklu lipoprotein LDL düzeyi ve paraoksanaz-1 PON-1 aktivitesi üzerine etkisini araştırmaktır. Yöntem: Çalışmaya AMİ tanısı konulan 31 hasta ve kontrol grubunu oluşturacak 15 olgu alındı. AMİ grubundan 15 hastaya karvedilol ve 16 hastaya metoprolol tedavisi verilerek çalışma iki guruba randomize edildi. Çalışmanın sonunda başvuru ve kontrol vizitinde alınan ve saklanan kan örneklerinden okside LDL’nin ve PON-1 aktivitesinin başvuru tedavi öncesi ve tedavi sonrası 1 aylık sonuçlarına bakıldı. Bulgular: Hasta grubunda kontrol grubuna kıyasla başlangıç HDL düzeyi ve PON-1 aktivitesi anlamlı derecede düşük olarak saptandı. Okside LDL düzeyi hasta grubunda kontrol grubuna göre daha yüksekti. Hasta grubunda 1 aylık karvedilol p=0,008 ve metoprolol p Sonuç: AMİ geçiren hastalarda diğer çalışmalara paralel olarak, okside LDL' nin arttığı ve HDL-K düzeyi ile PON-1 aktivitesinin azaldığı gösterildi. Antioksidan özellikleri nedeniyle Karvedilol’ün PON-1 aktivitesini arttırmada Metoprolol’e göre daha üstün olması beklenebilir. Fakat bir aylık süre bunu göstermek için yeterli olmayabilir.

Keywords

Koroner arter hastalığı, okside LDL, paraoksanaz-1

References

• 1.Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362(6423):801-9
• 2.Carmena R, Ascaso JF, Camejo G, Varela G, Hurt-Camejo E, Ordovas JM, et al. Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans. Atherosclerosis. 1996;125(2):243-55.
• 3.Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353(1):46-57
• 4.Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286(1-2): 152–4.
• 5.Mackness MI, Mackness B, Durrington PN, Connelly PW, HegeleRA. Paraoxonase: biochemistry, genetics and relationship to plasmalipoproteins. Curr Opin Lipidol 1996;7(2): 69–76.
• 6.Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26(7-8): 892–904.
• 7.Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 1983; 35(6): 1126-38.
• 8.Yusuf S, Sleight P, Rosi PRF, Ramsdale D, Peto R, Furze L, et al. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous beta-blockade in suspected acute myocardial infarction. Circulation 1983; 67 (6 Pt 2): I32-41.
• 9.Feuerstein GZ, Hamburger SA, Smith EF, Bril A, Ruffolo RR, Myocardial protection with Carvedilol. J Cardiovasc Pharmacol 1992; 19:S138-41.
• 10.McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem1986; 32(4): 671-3.
• 11.Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln-Argl92 polymorphism of human paraoxonase gene ıs not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998;18(10):1611-6.
• 12.Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000; 101(21): 2510-7.
• 13.Aviram M, Rosenblat M, Bisgair CL, Newton RS, PrimoParmo SL, La Du BN Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101(8): 1581-90.
• 14.Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96(6):2882–91.
• 15.Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103(15):1955–60.
• 16.Holvet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and Malondialdehyde-Modified LDL in Patients With Acute Coronary Syndromes and Stable Coronary Artery Disease. Circulation 1998;9(15)8:1487-1494.
• 17.Halliwell B, Gutteridge JM, Cross CE, Free radicals,antioxidants, and human disease: where are we now? J Lab Clin Med 1992:119(6):598-620.
• 18.Devasagayam TP, Tilac JC, Boloor KK Sane KS, Ghaskadbi SS, Lele RD. Free radicals and antioxidants in human health: curent status and future prospects. J Assoc Phisicians India 2004;52: 794-804.
• 19.Serdar Z, Serdar Z, Altın A, Albayrak S. et al. The relation between oxidant and antioxidant parameters and severity of acute coronary syndromes. Acta Cardiol 2007; 62(4):373-80.
• 20.Jialal I, Vega G, Grundy S. Physiological levels of ascorbate inhibit the oxidative modification of LDL. Atherosclerosis 1990;82(3):185–91.
• 21.Aviram M, Rosenblat M, Bisgair CL, Newton RS, PrimoParmo SL, La Du BN Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101(8): 1581-90.
• 22.Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J Am Med Assoc 1986;256(20):2835–8.